CoChat

The DOI matches its Crossref record; 208 of the 208 references it cites were found in a registry or an index.

Glucagon-like peptide-1: a multi-faceted anti-inflammatory agent

Open access

Abstract

Inflammation contributes to many chronic conditions. It is often associated with circulating pro-inflammatory cytokines and immune cells. GLP-1 levels correlate with disease severity. They are often elevated and can serve as markers of inflammation. Previous studies have shown that oxytocin, hCG, ghrelin, alpha-MSH and ACTH have receptor-mediated anti-inflammatory properties that can rescue cells from damage and death. These peptides have been studied well in the past century. In contrast, GLP-1 and its anti-inflammatory properties have been recognized only recently. GLP-1 has been proven to be a useful adjuvant therapy in type-2 diabetes mellitus, metabolic syndrome, and hyperglycemia. It also lowers HbA1C and protects cells of the cardiovascular and nervous systems by reducing inflammation and apoptosis. In this review we have explored the link between GLP-1, inflammation, and sepsis.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3389/fimmu.2023.1148209

Cites

208 of 208 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 GLP-1 synthesis: In the intestine — The proglucagon precursor gives rise to oxyntomodulin, GLP1 (and its two equipotent, truncated derivatives) and GLP-2. Like the GLPs, the intervening peptides (IP-1 and IP-2) may also have physiological functions (12, 13). In the pancreas, the proglucagon precursor yields glucagon and the glicentin-related pancreatic peptide (GRPP) (12–16) Figure modified from article 12. Figure from Open access (Molecular Metabolism) permissible to re-use under a CC-BY 4.0 license.
Figure 1 GLP-1 synthesis: In the intestine — The proglucagon precursor gives rise to oxyntomodulin, GLP1 (and its two equipotent, truncated derivatives) and GLP-2. Like the GLPs, the intervening peptides (IP-1 and IP-2) may also have physiological functions (12, 13). In the pancreas, the proglucagon precursor yields glucagon and the glicentin-related pancreatic peptide (GRPP) (12–16) Figure modified from article 12. Figure from Open access (Molecular Metabolism) permissible to re-use under a CC-BY 4.0 license.CC BY · PubMed Central
Figure 2 (Original by authors of the manuscript): The seven transmembrane alpha-helices are bound to G-protein subunits (19). These consist of alpha subunit and beta-gamma subunit complexes bound to GDP. In the inactive state, the α-subunit is bound to GDP. Upon binding of GLP-1, GDP is replaced by GTP, which then activates the α-subunit. The α-subunit and GTP complex activate signaling cascades through adenylyl cyclase and phospholipase C (20).The third intracellular loop is most important in receptor signaling.
Figure 2 (Original by authors of the manuscript): The seven transmembrane alpha-helices are bound to G-protein subunits (19). These consist of alpha subunit and beta-gamma subunit complexes bound to GDP. In the inactive state, the α-subunit is bound to GDP. Upon binding of GLP-1, GDP is replaced by GTP, which then activates the α-subunit. The α-subunit and GTP complex activate signaling cascades through adenylyl cyclase and phospholipase C (20).The third intracellular loop is most important in receptor signaling.CC BY · PubMed Central
Figure 3 GLP-1 receptor signaling (21-26). Figure modified from article 23. Figure from Open access (Gastroenterology) permissible to re-use under a CC-BY 4.0 license.
Figure 3 GLP-1 receptor signaling (21-26). Figure modified from article 23. Figure from Open access (Gastroenterology) permissible to re-use under a CC-BY 4.0 license.CC BY · PubMed Central
Figure 4 (Original by authors of the manuscript): Effects of GLP-1 on various organ systems (34–39).
Figure 4 (Original by authors of the manuscript): Effects of GLP-1 on various organ systems (34–39).CC BY · PubMed Central
Figure 5 Effects of glucagon-like peptide-1 receptor agonist on non-alcoholic fatty liver disease. PPAR-α, Peroxisome proliferator-activated receptor; IHL, intrahepatic lipids; AMPK, AMP-activated protein kinase; CRP, C reactive protein; AGEs, Advanced glycation and end products; JNK, c-Jun NH2-terminal kinase; GLP-1RA, Glucagon-like peptide-1 receptor agonist; NAFLD, Non-alcoholic fatty liver disease (53). Modified figure from reference 53. Figure from Open access (World Journal of Gastroenterology) permissible to re-use under a CC-BY 4.0 license).
Figure 5 Effects of glucagon-like peptide-1 receptor agonist on non-alcoholic fatty liver disease. PPAR-α, Peroxisome proliferator-activated receptor; IHL, intrahepatic lipids; AMPK, AMP-activated protein kinase; CRP, C reactive protein; AGEs, Advanced glycation and end products; JNK, c-Jun NH2-terminal kinase; GLP-1RA, Glucagon-like peptide-1 receptor agonist; NAFLD, Non-alcoholic fatty liver disease (53). Modified figure from reference 53. Figure from Open access (World Journal of Gastroenterology) permissible to re-use under a CC-BY 4.0 license).CC BY · PubMed Central
Figure 6 Overview of the main pathways induced by GLP-1 in neurons. Activation of the GLP-1R activates adenylyl cyclase and increases cAMP levels. This activates PKA and other downstream kinases related to growth factor signaling. GLP-1 supports neurogenesis, reduces inflammation, and inhibits apoptosis while improving learning and memory in the hippocampus.(modify from reference 130) (AATP, adenosine triphosphate; cAMP, Cyclic adenosine monophosphate; CREB, cAMP response element binding protein; PKA, protein kinase A; PI3K, phosphatidylinositol-3 kinase; PKC, protein kinase c; mTOR, Mammalian target of rapamycin; ERK, extracellular signal-regulated kinase; BRAF, v-raf murine sarcoma viral oncogene homolog B1.) Figure modified from reference 130, Open access (Peptides journal) permissible to re-use under a CC-BY 4.0 license).
Figure 6 Overview of the main pathways induced by GLP-1 in neurons. Activation of the GLP-1R activates adenylyl cyclase and increases cAMP levels. This activates PKA and other downstream kinases related to growth factor signaling. GLP-1 supports neurogenesis, reduces inflammation, and inhibits apoptosis while improving learning and memory in the hippocampus.(modify from reference 130) (AATP, adenosine triphosphate; cAMP, Cyclic adenosine monophosphate; CREB, cAMP response element binding protein; PKA, protein kinase A; PI3K, phosphatidylinositol-3 kinase; PKC, protein kinase c; mTOR, Mammalian target of rapamycin; ERK, extracellular signal-regulated kinase; BRAF, v-raf murine sarcoma viral oncogene homolog B1.) Figure modified from reference 130, Open access (Peptides journal) permissible to re-use under a CC-BY 4.0 license).CC BY · PubMed Central
Figure 7 Impact of GLP-1 on LPS-induced IL-1b mRNA production in rat astrocytes. ELISA investigation was performed at 360 min after LPS (100 ng/mL) or vehicle treatment with or without GLP-1 (1 mM) (72). Data represent the mean ± SEM. ***p<0.001. Figure modified from Open access (Neuroscience Research Journal) permissible to re-use under a CC-BY 4.0 license). ###p<.001.
Figure 7 Impact of GLP-1 on LPS-induced IL-1b mRNA production in rat astrocytes. ELISA investigation was performed at 360 min after LPS (100 ng/mL) or vehicle treatment with or without GLP-1 (1 mM) (72). Data represent the mean ± SEM. ***p<0.001. Figure modified from Open access (Neuroscience Research Journal) permissible to re-use under a CC-BY 4.0 license). ###p<.001.CC BY · PubMed Central
Figure 8 tMCAO, Transient middle cerebral artery occlusion (132): 1-The level of COX-2 was significantly increased at 48 h after tMCAO. Treatment with ex-4 restored COX-2 to the basal level after tMCAO in the rat brain. Ex9-39 treatment increased COX-2 levels as much as vehicle Group.(***p<0.001, compared to sham operated group, ###p<0.001, compared to chemical group) 2-The level of PGE2, which is product of COX-2 activity, was increased by 1 h tMCAO, but this level was attenuated by ex-4 (n =5, **p<0.01, compared to the sham-operated group. (1) Data represent the mean ± SEM. ***p<0.001, ###p<0.001, (2) Data represent the mean ± SEM. **p<0.01. Figure modified from Open access (Experimental Neurobiology) permissible to re-use under a CC-BY 4.0 license).
Figure 8 tMCAO, Transient middle cerebral artery occlusion (132): 1-The level of COX-2 was significantly increased at 48 h after tMCAO. Treatment with ex-4 restored COX-2 to the basal level after tMCAO in the rat brain. Ex9-39 treatment increased COX-2 levels as much as vehicle Group.(***p<0.001, compared to sham operated group, ###p<0.001, compared to chemical group) 2-The level of PGE2, which is product of COX-2 activity, was increased by 1 h tMCAO, but this level was attenuated by ex-4 (n =5, **p<0.01, compared to the sham-operated group. (1) Data represent the mean ± SEM. ***p<0.001, ###p<0.001, (2) Data represent the mean ± SEM. **p<0.01. Figure modified from Open access (Experimental Neurobiology) permissible to re-use under a CC-BY 4.0 license).CC BY · PubMed Central
Figure 9 Treatment with exendin-4 was accompanied by increased expression of GLP-1R, while treatment with the GLP-1R antagonist, exendin-9-39 (antagonist), did not show this neuroprotective effect in stroke(n=4, *p<0.05, compared to sham-operated group, #p<0.01, compared to the chemical-treated group). Data represent the mean ± SEM. *P<.05; #P<0.01 (132). Figure modified from Open access (Experimental Neurobiology) permissible to re-use under a CC-BY 4.0 license).
Figure 9 Treatment with exendin-4 was accompanied by increased expression of GLP-1R, while treatment with the GLP-1R antagonist, exendin-9-39 (antagonist), did not show this neuroprotective effect in stroke(n=4, *p<0.05, compared to sham-operated group, #p<0.01, compared to the chemical-treated group). Data represent the mean ± SEM. *P<.05; #P<0.01 (132). Figure modified from Open access (Experimental Neurobiology) permissible to re-use under a CC-BY 4.0 license).CC BY · PubMed Central
Figure 10 Obesity and consumption of foods high in advanced glycation end-products (red circles, AGEs) create a pro-inflammatory state through dysregulated arginine metabolism (increasing arginase activity and production of ADMA, in red) and activating RAGE-mediated, NF-kB inflammation (pink star). ADMA also inhibits endothelial NOS (eNOS) and increases NF-kB activity. GLP-1 production is spurred by consumption of L-arginine (green circles) and when it binds its receptor, it activates protein kinase A (blue octagon). This activity blunts RAGE-mediated inflammation and production of ADMA (blue T-lines). The GLP-1 pathway is also a target of treatments for diabetes and obesity. GLP-1 is rapidly degraded by DPP-4, and DPP-4 inhibitors (gliptins) are used to increase GLP-1. GLP-1 receptor agonists (exenatide and liraglutide) are also available (148). Figure modified from article 147 Open access (Journal of Immunology Research) permissible to re-use under a CC-BY 4.0 license).
Figure 10 Obesity and consumption of foods high in advanced glycation end-products (red circles, AGEs) create a pro-inflammatory state through dysregulated arginine metabolism (increasing arginase activity and production of ADMA, in red) and activating RAGE-mediated, NF-kB inflammation (pink star). ADMA also inhibits endothelial NOS (eNOS) and increases NF-kB activity. GLP-1 production is spurred by consumption of L-arginine (green circles) and when it binds its receptor, it activates protein kinase A (blue octagon). This activity blunts RAGE-mediated inflammation and production of ADMA (blue T-lines). The GLP-1 pathway is also a target of treatments for diabetes and obesity. GLP-1 is rapidly degraded by DPP-4, and DPP-4 inhibitors (gliptins) are used to increase GLP-1. GLP-1 receptor agonists (exenatide and liraglutide) are also available (148). Figure modified from article 147 Open access (Journal of Immunology Research) permissible to re-use under a CC-BY 4.0 license).CC BY · PubMed Central
Figure 11 Diet and obesity may lead to dysregulated arginine metabolism and increase the production of advanced glycation end products (AGE) with subsequent activation of their receptor (RAGE), contributing to inflammation and asthma. The enhancing GLP-1 pathway may be the key to reducing this inflammation (148). Figure modified from articles 147 (Figure from Open access (Journal of Immunology Research) permissible to re-use under a CC-BY 4.0 license).
Figure 11 Diet and obesity may lead to dysregulated arginine metabolism and increase the production of advanced glycation end products (AGE) with subsequent activation of their receptor (RAGE), contributing to inflammation and asthma. The enhancing GLP-1 pathway may be the key to reducing this inflammation (148). Figure modified from articles 147 (Figure from Open access (Journal of Immunology Research) permissible to re-use under a CC-BY 4.0 license).CC BY · PubMed Central
Figure 12 Use of GLP-1 Exendin-4 results in a) normalizes CRP levels in serum and medium b) low levels of MMP-9 and low MMP-9/TIMP ratios in serum and medium. (A) Data represent the mean ± SEM. *P<.05; **P<0.001, (B) Data represent the mean ± SEM. *P<.05; **P<0.01; ***P< 0.001 (182). Figure modified from article 183. Figure from Open access (European journal of pharmacology) permissible to re-use under a CC-BY 4.0 license).
Figure 12 Use of GLP-1 Exendin-4 results in a) normalizes CRP levels in serum and medium b) low levels of MMP-9 and low MMP-9/TIMP ratios in serum and medium. (A) Data represent the mean ± SEM. *P<.05; **P<0.001, (B) Data represent the mean ± SEM. *P<.05; **P<0.01; ***P< 0.001 (182). Figure modified from article 183. Figure from Open access (European journal of pharmacology) permissible to re-use under a CC-BY 4.0 license).CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 208 references

Cited by

See all 344

Metadata

Authors
Mehdi, S. F., Pusapati, S., Anwar, M. S., Lohana, D., Kumar, P., Nandula, S. A., Nawaz, F. K., Tracey, K., Yang, H., LeRoith, D., Brownstein, M. J., & Roth, J.
Affiliations
  • Northwell Health (US)
  • Icahn School of Medicine at Mount Sinai (US)
  • Azevan Pharmaceuticals (United States) (US)
Corresponding author
Roth, Jesse
Venue
Frontiers in Immunology
Published
2023-05-17
Volume
14
Pages
1148209-1148209
ISSN
1664-3224 (ISSN-L)
OpenAlex
W4377041419
Cited by
317
References
208
Citations by year
2026: 107 · 2025: 138 · 2024: 61 · 2023: 10
FWCI
11.40
Type
journal article
Language
en
Open access
Locations
  • Frontiers in Immunology (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
Feinstein Institutes for Medical Research
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuropeptides and Animal Physiology
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adipokines, Inflammation, and Metabolic Diseases
Keywords
glucagon-like peptide-1, anti-inflammatory peptides, inflammation, sepsis, inflammatory cytokines, type 2 diabetes, metabolic syndrome, hyperglycemia, HbA1c, apoptosis, cardioprotection, neuroprotection, adjuvant therapy
MeSH terms
Anti-Inflammatory Agents, Diabetes Mellitus, Type 2, Humans, Inflammation, Peptides, Glucagon-Like Peptide 1

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Glucagon-like peptide-1: a multi-faceted anti-inflammatory agent. https://app.cochat.ai/papers/10.3389/fimmu.2023.1148209
The paper
Mehdi, S. F., Pusapati, S., Anwar, M. S., Lohana, D., Kumar, P., Nandula, S. A., Nawaz, F. K., Tracey, K., Yang, H., LeRoith, D., Brownstein, M. J., & Roth, J. (2023). Glucagon-like peptide-1: a multi-faceted anti-inflammatory agent. Frontiers in Immunology. https://doi.org/10.3389/fimmu.2023.1148209

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.